Rosuvastatin Add On Metformin In The Treatment Of Polycystic Ovarian Syndrome

Abstract

Background:-Polycystic ovary syndrome (PCOS) is common in women of reproductive age and it’s commonly associated with endocrinal and biochemical derangements. Moreover PCOS also associated with increase cardiovascular risks such as adverse lipid profile and endothelial dysfunction. Recently, statins have been shown to improve endocrine and metabolic aspects of PCOS.
Aim of the study:-The aim of this study was to evaluate effects of rosuvastatin as adjuvant therapy in treatment of polycystic ovarian syndrome.
Materials and methods:-The study was conducted at Al-Kadhemia Teaching Hospital, Department of Obstetrics and Gynecology from February 2014 to December 2015. In this study 96 women with PCOS randomly divided equally to two study groups; Group (A) in which patients were allocated to receive metformin (500 mg three times a day) plus rosuvastatin (10 mg/day) and group (B) in which patients were allocated to receive metformin (500 mg three times a day)plus placebo for 12 weeks. Blood samples were obtained before and after treatment for determination of fasting blood sugar, follicle stimulating hormone, luteinizing hormone, Dehydroepiandrosterone sulfate, serum testosterone and total lipid profile.
Results:-At the end of study period, 89 patients complete the study (45 patients in Group A vs 44 patients in Group B). There were a significant decreases observed in both groups with respect to body mass index, fasting blood glucose, testosterones and luteinizing hormone whereas dehydroepiandrosterone sulfate, total cholesterol, low-density lipoprotein cholesterol and triglyceride declined significantly only in Group A.
Conclusions:-Rosuvastatin as adjuvant therapy in patients with polycystic ovarian syndrome has many beneficial effects.